Lexaria Bioscience Corp.

LEXX

$12.57

+2.05%

2026-09-04 13:11:00 EDT+$0.25

Salud

Biotecnología

NASDAQ

Negociación activa

Lexaria Bioscience Corp. es una empresa de biotecnología centrada en la administración avanzada de fármacos. Su tecnología DehydraTECH patentada y propietaria está ...

Cadena de suministro de LEXX

Aguas arriba

Fundiciones, empaquetado, memoria, obleas, componentes y proveedores de insumos.

Aguas arriba

InClin, Inc.

Unnamed CRO (GLP-1 Studies)

BevNology

Third-Party Material/API Suppliers (Unnamed)

Third-Party Regulatory Affairs Consultant (Unnamed)

Standard Lab Equipment Suppliers (Unnamed)

InClin, Inc.

Contract Research Organization (CRO) — manages clinical trials for hypertension (HYPER-H23-1 Phase 1b study) and potentially GLP-1 programs; handles site management, data collection, and regulatory monitoring

Unnamed CRO (GLP-1 Studies)

Contract Research Organization — contracted in 2024 and 2026 to execute 12-week chronic GLP-1 human study (GLP-1-H24-4) and GLP-1 biodistribution and animal studies

BevNology

Manufacturing operating partner — Lexaria installed commercial DehydraTECH manufacturing equipment at BevNology's facility for production of powdered and liquid DehydraTECH formulations

Third-Party Material/API Suppliers (Unnamed)

Suppliers of raw materials, excipients, and active pharmaceutical ingredients used in DehydraTECH formulation development and manufacturing; Lexaria's 10-K notes dependency on third-party suppliers for analytical and production services

Third-Party Regulatory Affairs Consultant (Unnamed)

Regulatory consultant assisting with FDA IND applications, protocol amendments, and response to FDA requests for clinical trial submissions

Aguas abajo

Clientes, distribuidores, OEM y canales que absorben la producción.

Aguas abajo

Altria Group, Inc.

PharmaCO (Anonymous Global Pharmaceutical Company)

SulfoSyn Limited

Premier Wellness Science Co., Ltd. (subsidiary of Premier Anti-Aging Co., Ltd.)

AnodGen Bioceuticals

BevNology

Hill Street Beverage Company (now Hill Inc.)

Altria Group, Inc.

NYSE:MO

Exclusive licensee of DehydraTECH technology for smokeless oral nicotine product development; Altria Ventures invested up to $12M in research funding. License includes royalty payments on worldwide revenues from oral nicotine products using DehydraTECH.

PharmaCO (Anonymous Global Pharmaceutical Company)

Unconfirmed

Material Transfer Agreement (MTA) since September 2024, extended through December 2026, to evaluate DehydraTECH for oral delivery of GLP-1 drugs. Includes temporary exclusive license. The partner's identity is confidential but described as a large multinational pharmaceutical company.

SulfoSyn Limited

Global exclusive license for all non-pharmaceutical uses of DehydraTECH-sulforaphane worldwide. Includes sub-licensing rights, minimum ongoing payments, and royalties. Lexaria also contracted as manufacturer.

Premier Wellness Science Co., Ltd. (subsidiary of Premier Anti-Aging Co., Ltd.)

TYO:4934

Exclusive license for DehydraTECH technology in the Japanese non-pharmaceutical cannabinoid market. Premier purchased rights and launched the "Ko" brand for CBD products in Japan.

AnodGen Bioceuticals

Five-year non-exclusive license for DehydraTECH-processed cannabinoid API powders. AnodGen has rights to manufacture and sell API powders to third parties. Based in Ireland, operates as a CDMO.

Comparables

Empresas cotizadas comparables y valores de seguimiento usados como representantes del análisis.

Comparables

Catalent, Inc.

Lonza Group AG

Enteris BioPharma (wholly owned by Spruce Biosciences)

Rani Therapeutics Holdings, Inc.

Catalent, Inc.

NYSE:CTLT

Leading drug delivery technology and CDMO company; provides comparable oral drug delivery formulation and manufacturing services across a broad range of therapeutics. Serves as a scaled, commercial-stage proxy for the type of drug delivery platform Lexaria aspires to become.

Lonza Group AG

SWX:LONN

Global CDMO and drug delivery technology leader with oral solid dosage, capsule, and formulation capabilities. Represents the large-cap end of the drug delivery/CDMO ecosystem.

Enteris BioPharma (wholly owned by Spruce Biosciences)

Unconfirmed

Specialist in oral peptide drug delivery technology (Peptelligence™), directly comparable to Lexaria's DehydraTECH for oral GLP-1 and peptide delivery. Private, but serves as a pure-play drug delivery technology competitor proxy.

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Development-stage biotech focused on oral delivery of biologics and peptides via robotic pill technology. Direct comparable as an oral drug delivery platform company targeting GLP-1 and other injectable-to-oral conversion opportunities.

Geografía

Exposiciones regionales que pueden distorsionar la red de suministro.

Geografía

Canada (British Columbia)

United States

Japan

Lexaria Bioscience Corp. (Kelowna, BC)

BevNology (Fayetteville, Georgia)

InClin, Inc. (San Mateo, California)

Altria Group, Inc. (Richmond, Virginia)

Premier Wellness Science Co., Ltd. / Premier Anti-Aging Co., Ltd. (Tokyo)

Canada (British Columbia)

Headquarters & R&D Operations

Lexaria Bioscience Corp. (Kelowna, BC)NASDAQ:LEXXCorporate headquarters and licensed in-house formulation development and research laboratory

United States

Clinical Trials & Manufacturing

BevNology (Fayetteville, Georgia)Manufacturing partner housing DehydraTECH commercial equipment

InClin, Inc. (San Mateo, California)CRO managing Lexaria's U.S. clinical trials

Altria Group, Inc. (Richmond, Virginia)NYSE:MOLargest financial licensee for nicotine products

Japan

Licensee Market

Premier Wellness Science Co., Ltd. / Premier Anti-Aging Co., Ltd. (Tokyo)TYO:4934Exclusive licensee for Japanese non-pharmaceutical cannabinoid market

Ireland

CDMO & Licensee Operations

AnodGen Bioceuticals (Ireland)Non-exclusive cannabinoid API license and CDMO

SulfoSyn Limited (Dublin, Ireland)Global exclusive licensee for sulforaphane applications

Canada (Toronto/TSXV)

Listed Partner

Hill Inc. (formerly Hill Street Beverage Company)TSXV:HILLJoint manufacturing and licensing partner for cannabis beverages

Concentración

Exposiciones de concentración de clientes, proveedores o socios que pueden distorsionar la red de suministro.

Customer

Critical

Extreme customer concentration risk — Lexaria's revenue is almost entirely dependent on a small number of licensing partners. IP Licensing accounts for 98.6% of FY2025 revenue. The Altria license and anonymous PharmaCO MTA represent the two most financially significant relationships; loss of either would be critical.

Other

Critical

Stage-of-development risk — Lexaria is a pre-commercial (clinical-stage) company with minimal revenue (~$706K in FY2025). Going concern risk noted in SEC filings. Cash burn of ~$6.7M/year (historical). No approved products generating stable revenue.

Other

High

Single technology platform risk — Entire business depends on DehydraTECH technology. If competing drug delivery technologies (e.g., oral peptide delivery from Novo Nordisk, Eli Lilly, Enteris BioPharma, or Rani Therapeutics) prove superior, DehydraTECH could be rendered obsolete.

Other

Medium

Third-party dependency risk — Relies on CROs (InClin and others) for clinical trial execution, third-party suppliers for materials/manufacturing, and external regulatory consultants for FDA interactions. Any failure by these partners directly impacts Lexaria's development timelines.

Foundry

Medium

Manufacturing concentration — BevNology serves as the primary commercial manufacturing site for DehydraTECH products. Single-point-of-failure risk if BevNology's facility is disrupted. Equipment already moved and installed at BevNology.

Composición de ingresos

Cómo la composición de ingresos se traduce en apalancamiento y dependencia en la cadena de suministro.

IP Licensing

98.6%

$0.0B

Core revenue driver; reflects upfront fees, milestone payments, and royalties from licensees using DehydraTECH technology. Revenue is non-recurring and dependent on securing new licensing partners.

B2B (Business-to-Business)

1.4%

$0.0B

Minimal revenue from manufacturing services and material supply agreements with partners such as BevNology. Insignificant scale; indicates pre-commercial stage.

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal

Lexaria Bioscience Corp.

Cadena de suministro de LEXX

Aguas arriba

InClin, Inc.

Unnamed CRO (GLP-1 Studies)

BevNology

Third-Party Material/API Suppliers (Unnamed)

Third-Party Regulatory Affairs Consultant (Unnamed)

Standard Lab Equipment Suppliers (Unnamed)

Aguas abajo

Altria Group, Inc.

PharmaCO (Anonymous Global Pharmaceutical Company)

SulfoSyn Limited

Premier Wellness Science Co., Ltd. (subsidiary of Premier Anti-Aging Co., Ltd.)

AnodGen Bioceuticals

BevNology

Hill Street Beverage Company (now Hill Inc.)

Comparables

Catalent, Inc.

Lonza Group AG

Enteris BioPharma (wholly owned by Spruce Biosciences)

Rani Therapeutics Holdings, Inc.

Geografía

Canada (British Columbia)

United States

Japan

View More

Cadena de suministro de LEXX

Aguas arriba

InClin, Inc.

Unnamed CRO (GLP-1 Studies)

BevNology

Third-Party Material/API Suppliers (Unnamed)

Third-Party Regulatory Affairs Consultant (Unnamed)

Standard Lab Equipment Suppliers (Unnamed)

Aguas abajo

Altria Group, Inc.

PharmaCO (Anonymous Global Pharmaceutical Company)

SulfoSyn Limited

Premier Wellness Science Co., Ltd. (subsidiary of Premier Anti-Aging Co., Ltd.)

AnodGen Bioceuticals

BevNology

Hill Street Beverage Company (now Hill Inc.)

Comparables

Catalent, Inc.

Lonza Group AG

Enteris BioPharma (wholly owned by Spruce Biosciences)

Rani Therapeutics Holdings, Inc.

Geografía

Canada (British Columbia)

United States

Japan

View More